Which has higher valuation & earnings, MDWD or NGNE?

MediWound has higher revenue and earnings than Neurogene. MediWound is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 10.34 -$23.88M -$1.80 N/A Neurogene $930K 665.49 -$90.35M -$5.03 N/A

Is MDWD or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Neurogene's return on equity of -45.10% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -170.10% -47.24% -24.27% Neurogene N/A -45.10% -41.00%

Does the media favor MDWD or NGNE?

In the previous week, MediWound had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for MediWound and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.49 beat MediWound's score of 0.33 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTMX or MDWD?

In the previous week, MediWound had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for MediWound and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.62 beat MediWound's score of 0.33 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MDWD or IRWD?

In the previous week, MediWound had 3 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for MediWound and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.59 beat MediWound's score of 0.33 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, MDWD or VSTM?

MediWound has higher earnings, but lower revenue than Verastem. MediWound is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 10.34 -$23.88M -$1.80 N/A Verastem $30.91M 23.97 -$209.47M -$2.66 N/A

Is MDWD or VSTM more profitable?

MediWound has a net margin of -170.10% compared to Verastem's net margin of -231.59%. MediWound's return on equity of -47.24% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -170.10% -47.24% -24.27% Verastem -231.59% -467.49% -94.54%

Does the media refer more to MDWD or VSTM?

In the previous week, Verastem had 7 more articles in the media than MediWound. MarketBeat recorded 12 mentions for Verastem and 5 mentions for MediWound. MediWound's average media sentiment score of 0.33 beat Verastem's score of 0.13 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, MDXG or MDWD?

MiMedx Group has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $355.17M 1.96 $48.58M $0.04 119.25 MediWound $16.96M 10.34 -$23.88M -$1.80 N/A

Is MDXG or MDWD more profitable?

MiMedx Group has a net margin of 1.76% compared to MediWound's net margin of -170.10%. MiMedx Group's return on equity of 12.09% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% MediWound -170.10% -47.24% -24.27%

Does the media prefer MDXG or MDWD?

In the previous week, MediWound had 2 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for MediWound and 3 mentions for MiMedx Group. MediWound's average media sentiment score of 0.33 beat MiMedx Group's score of 0.32 indicating that MediWound is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MediWound (MDWD) Competitors

$13.65 -0.30 (-2.15%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$13.55 -0.10 (-0.73%)

As of 04:00 AM Eastern

Compare

MDWD vs. NGNE, CTMX, IRWD, VSTM, and MDXG

Should you buy MediWound stock or one of its competitors? MediWound's main competitors and comparable companies include Neurogene (NGNE), CytomX Therapeutics (CTMX), Ironwood Pharmaceuticals (IRWD), Verastem (VSTM), and MiMedx Group (MDXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MediWound compare to Neurogene?

MediWound (NASDAQ:MDWD) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

46.8% of MediWound shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Neurogene has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Neurogene's return on equity of -45.10% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Neurogene	N/A	-45.10%	-41.00%

In the previous week, MediWound had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for MediWound and 3 mentions for Neurogene. Neurogene's average media sentiment score of 0.49 beat MediWound's score of 0.33 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MediWound has higher revenue and earnings than Neurogene. MediWound is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.34	-$23.88M	-$1.80	N/A
Neurogene	$930K	665.49	-$90.35M	-$5.03	N/A

MediWound presently has a consensus target price of $33.00, suggesting a potential upside of 141.76%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 170.50%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

MediWound has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

Summary

Neurogene beats MediWound on 12 of the 17 factors compared between the two stocks.

How does MediWound compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

CytomX Therapeutics currently has a consensus price target of $11.90, indicating a potential upside of 328.06%. MediWound has a consensus price target of $33.00, indicating a potential upside of 141.76%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
MediWound	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

CytomX Therapeutics has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.95	-$17.37M	-$0.50	N/A
MediWound	$16.96M	10.34	-$23.88M	-$1.80	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MediWound has a net margin of -170.10% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
MediWound	-170.10%	-47.24%	-24.27%

In the previous week, MediWound had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for MediWound and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.62 beat MediWound's score of 0.33 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market.

Summary

CytomX Therapeutics beats MediWound on 12 of the 17 factors compared between the two stocks.

How does MediWound compare to Ironwood Pharmaceuticals?

MediWound (NASDAQ:MDWD) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

In the previous week, MediWound had 3 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for MediWound and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.59 beat MediWound's score of 0.33 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediWound currently has a consensus target price of $33.00, indicating a potential upside of 141.76%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 45.98%. Given MediWound's higher probable upside, equities analysts plainly believe MediWound is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

MediWound has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.34	-$23.88M	-$1.80	N/A
Ironwood Pharmaceuticals	$296.15M	2.38	$24.02M	$0.77	5.55

46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ironwood Pharmaceuticals beats MediWound on 11 of the 17 factors compared between the two stocks.

How does MediWound compare to Verastem?

MediWound (NASDAQ:MDWD) and Verastem (NASDAQ:VSTM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

MediWound has higher earnings, but lower revenue than Verastem. MediWound is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.34	-$23.88M	-$1.80	N/A
Verastem	$30.91M	23.97	-$209.47M	-$2.66	N/A

MediWound presently has a consensus price target of $33.00, indicating a potential upside of 141.76%. Verastem has a consensus price target of $13.83, indicating a potential upside of 69.11%. Given MediWound's higher probable upside, equities research analysts clearly believe MediWound is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

46.8% of MediWound shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 1.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MediWound has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market. Comparatively, Verastem has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

In the previous week, Verastem had 7 more articles in the media than MediWound. MarketBeat recorded 12 mentions for Verastem and 5 mentions for MediWound. MediWound's average media sentiment score of 0.33 beat Verastem's score of 0.13 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

MediWound has a net margin of -170.10% compared to Verastem's net margin of -231.59%. MediWound's return on equity of -47.24% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Verastem	-231.59%	-467.49%	-94.54%

Summary

Verastem beats MediWound on 9 of the 17 factors compared between the two stocks.

How does MediWound compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, MediWound had 2 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for MediWound and 3 mentions for MiMedx Group. MediWound's average media sentiment score of 0.33 beat MiMedx Group's score of 0.32 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to MediWound's net margin of -170.10%. MiMedx Group's return on equity of 12.09% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
MediWound	-170.10%	-47.24%	-24.27%

MiMedx Group presently has a consensus target price of $8.57, indicating a potential upside of 79.69%. MediWound has a consensus target price of $33.00, indicating a potential upside of 141.76%. Given MediWound's higher possible upside, analysts clearly believe MediWound is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
MediWound	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

MiMedx Group has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

MiMedx Group has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$355.17M	1.96	$48.58M	$0.04	119.25
MediWound	$16.96M	10.34	-$23.88M	-$1.80	N/A

Summary

MiMedx Group beats MediWound on 11 of the 16 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$179.29M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-7.58	13.88	274.07	25.69
Price / Sales	10.34	1,356.95	643.13	79.17
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	4.01	15.40	10.47	6.32
Net Income	-$23.88M	-$22.82M	$3.49B	$359.73M
7 Day Performance	2.25%	-1.71%	-0.67%	0.17%
1 Month Performance	5.00%	-6.18%	-3.17%	-3.27%
1 Year Performance	-24.25%	30.64%	15.13%	5.58%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	2.3006 of 5 stars	$13.65 -2.2%	$33.00 +141.8%	-23.6%	$179.29M	$16.96M	N/A	121
NGNE Neurogene	2.4129 of 5 stars	$33.69 -4.3%	$83.67 +148.3%	+83.6%	$704.60M	$930K	N/A	131
CTMX CytomX Therapeutics	2.42 of 5 stars	$2.69 -15.9%	$11.90 +342.4%	+31.8%	$697.28M	$76.20M	N/A	69	High Trading Volume
IRWD Ironwood Pharmaceuticals	2.5516 of 5 stars	$4.06 -2.6%	$6.23 +53.5%	+207.2%	$689.05M	$296.15M	5.27	100
VSTM Verastem	3.0632 of 5 stars	$7.34 -2.3%	$13.83 +88.5%	-11.0%	$680.13M	$30.91M	N/A	102

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. NGNE, CTMX, IRWD, VSTM, and MDXG

How does MediWound compare to Neurogene?

Summary

How does MediWound compare to CytomX Therapeutics?

Summary

How does MediWound compare to Ironwood Pharmaceuticals?

Summary

How does MediWound compare to Verastem?

Summary

How does MediWound compare to MiMedx Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. NGNE, CTMX, IRWD, VSTM, and MDXG

How does MediWound compare to Neurogene?

Do insiders and institutionals have more ownership in MDWD or NGNE?

Is MDWD or NGNE more profitable?

Does the media favor MDWD or NGNE?

Which has higher valuation & earnings, MDWD or NGNE?

Do analysts prefer MDWD or NGNE?

Which has more volatility & risk, MDWD or NGNE?

Summary

How does MediWound compare to CytomX Therapeutics?

Do analysts prefer CTMX or MDWD?

Which has preferable valuation and earnings, CTMX or MDWD?

Do institutionals and insiders have more ownership in CTMX or MDWD?

Is CTMX or MDWD more profitable?

Does the media prefer CTMX or MDWD?

Which has more risk & volatility, CTMX or MDWD?

Summary

How does MediWound compare to Ironwood Pharmaceuticals?

Is MDWD or IRWD more profitable?

Does the media refer more to MDWD or IRWD?

Do analysts prefer MDWD or IRWD?

Which has more risk and volatility, MDWD or IRWD?

Which has higher valuation and earnings, MDWD or IRWD?

Do institutionals & insiders believe in MDWD or IRWD?

Summary

How does MediWound compare to Verastem?

Which has preferable earnings & valuation, MDWD or VSTM?

Do analysts prefer MDWD or VSTM?

Do institutionals and insiders believe in MDWD or VSTM?

Which has more volatility and risk, MDWD or VSTM?

Does the media refer more to MDWD or VSTM?

Is MDWD or VSTM more profitable?

Summary

How does MediWound compare to MiMedx Group?

Do insiders and institutionals believe in MDXG or MDWD?

Does the media prefer MDXG or MDWD?

Is MDXG or MDWD more profitable?

Do analysts recommend MDXG or MDWD?

Which has more risk and volatility, MDXG or MDWD?

Which has better earnings & valuation, MDXG or MDWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools